Marker Therapeutics Inc (MRKR)

$2.46 -0.20 (-7.52%)
Market Cap 28.48M
Revenue (ttm) 3.31M
Net Income (ttm) -8.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -248.94%
Debt to Equity Ratio 0.00
Volume 48,700
Avg Vol 59,818
Day's Range N/A - N/A
Shares Out 10.71M
Stochastic %K 18%
Beta 1.48
Analysts Strong Sell
Price Target $19.00

Latest News on MRKR

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:06 AM EST - 4 weeks ago

Marker Therapeutics Announces $16.1 Million Private Placement

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 19, 2024, 8:05 AM EST - 4 weeks ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 17, 2024, 7:00 AM EST - 4 weeks ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Dec 10, 2024, 8:30 AM EST - 5 weeks ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 26, 2024, 11:00 AM EST - 7 weeks ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 14, 2024, 4:30 PM EST - 2 months ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 5 months ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Aug 12, 2024, 7:00 AM EDT - 5 months ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 15, 2024, 4:15 PM EDT - 8 months ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Apr 8, 2024, 7:00 AM EDT - 10 months ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 25, 2024, 5:45 PM EDT - 10 months ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 22, 2024, 12:30 PM EDT - 10 months ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 22, 2024, 7:30 AM EST - 1 year ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Jan 8, 2024, 8:24 AM EST - 1 year ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Dec 21, 2023, 11:00 AM EST - 1 year ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 5:00 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Sep 11, 2023, 7:00 AM EDT - 1 year ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 17, 2023, 9:03 AM EDT - 1 year ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 4:30 PM EDT - 1 year ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Aug 7, 2023, 7:00 AM EDT - 1 year ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jul 10, 2023, 7:00 AM EDT - 1 year ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 26, 2023, 7:00 AM EDT - 1 year ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Jun 12, 2023, 7:00 AM EDT - 1 year ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 31, 2023, 6:30 AM EDT - 1 year ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 8, 2023, 7:30 AM EDT - 1 year ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

May 1, 2023, 7:30 AM EDT - 1 year ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Mar 22, 2023, 8:10 AM EDT - 1 year ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Dec 13, 2022, 7:00 AM EST - 2 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 13, 2022, 7:00 AM EDT - 2 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Sep 8, 2022, 7:00 AM EDT - 2 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Aug 11, 2022, 4:22 PM EDT - 2 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Aug 4, 2022, 4:37 PM EDT - 2 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 13, 2022, 7:00 AM EDT - 2 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

May 4, 2022, 10:30 AM EDT - 2 years ago

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Mar 17, 2022, 5:45 PM EDT - 3 years ago

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Marker Therapeutics to Present at Two Upcoming March Investor Conferences

Mar 7, 2022, 4:05 PM EST - 3 years ago

Marker Therapeutics to Present at Two Upcoming March Investor Conferences

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

Feb 17, 2022, 1:08 PM EST - 3 years ago

Why Are Marker Therapeutics Shares Trading Lower On Thursday?

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

Feb 16, 2022, 4:30 PM EST - 3 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

Feb 8, 2022, 4:05 PM EST - 3 years ago

Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer

Jan 20, 2022, 6:38 AM EST - 3 years ago

Marker Therapeutics Stock Gains On FDA Orphan Drug Tag For Second MultiTAA-Cell Therapy For Pancreatic Cancer

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Jan 19, 2022, 4:49 PM EST - 3 years ago

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

Dec 9, 2021, 7:00 AM EST - 3 years ago

Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting

Nov 18, 2021, 4:05 PM EST - 3 years ago

Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

Nov 10, 2021, 4:05 PM EST - 3 years ago

Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

Marker Therapeutics to Present at Three Upcoming September Investor Conferences

Sep 7, 2021, 4:05 PM EDT - 3 years ago

Marker Therapeutics to Present at Three Upcoming September Investor Conferences

Marker Therapeutics Secures $13.1M Grant To Support MultiTAA Cell Therapy Trial

Aug 20, 2021, 6:32 AM EDT - 3 years ago

Marker Therapeutics Secures $13.1M Grant To Support MultiTAA Cell Therapy Trial

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas

Aug 19, 2021, 4:05 PM EDT - 3 years ago

Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results

Aug 10, 2021, 4:01 PM EDT - 3 years ago

Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility

Jul 28, 2021, 4:05 PM EDT - 3 years ago

Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility